Introduction
============

Biliary tract carcinomas (BTCs), which include gallbladder carcinomas (GBCs) and cholangiocarcinomas (bile duct cancer), are rapidly growing lethal tumors associated with the digestive system ([@b1-or-0-0-7177]). The 5-year survival rate is \<10% in patients with advanced or metastatic BTCs ([@b2-or-0-0-7177]). Since the current treatments are minimally effective, a multi-omic approach combining genomic, transcriptomic, and metabonomic landscapes would be beneficial and could lead to improved treatments and possibly earlier diagnosis.

At present, the concept of precision or personalized medicine as a treatment strategy for many types of cancer has been widely recognized ([@b3-or-0-0-7177]). When utilizing this type of treatment strategy, one or several actionable mutations typically provide drug targets. Thus, appropriate biopsies and technologies are required to identify relevant biomarkers, such as single nucleotide variations (SNVs), insertion and deletions (Indels), gene fusions, copy number variations (CNVs), or aberrant expression ([@b4-or-0-0-7177]). Previous studies examining biliary tract tumors have utilized genetic mutational profiling ([@b5-or-0-0-7177]). Moreover, in BTCs, gene mutations in *ERBB2, PIK3CA, FGFR*, and *IDH1* have been utilized as drug targets ([@b6-or-0-0-7177]--[@b9-or-0-0-7177]). However, obtaining BTC tissue samples is challenging due to the anatomical complexity of the biliary tract system. These tumors are typically characterized by a small lesion size, potentially severe biliary hemorrhaging, and a high perforation risk, which limits the use of endoscopic retrograde cholangiopancreatography (ERCP) with intraductal ultrasonography (IDUS)-guided fine needle aspiration. A promising solution is the use of cell-free DNA (cfDNA), DNA released by tumor and normal cells that could potentially be the basis for liquid biopsies. This could provide tumor genomic information in a less invasive way than the current methods ([@b10-or-0-0-7177]). Previous studies have revealed that cfDNA can be utilized to identify actionable mutations and predict therapeutic responses in non-small cell lung cancer (NSCLC) ([@b11-or-0-0-7177]--[@b14-or-0-0-7177]). In the present study, bile cfDNA that was obtained from BTC patients as a minimally invasive 'liquid biopsy' method was subsequently examined using targeted deep sequencing to identify somatic variants.

Materials and methods
=====================

### Clinical specimens and data collection

The present study was approved by the Ethics Committee of the Shanghai Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University (Second Military Medical University) (EHBHKY2018-K-003). Ten BTC patients, four with gallbladder carcinomas and six with cholangiocarcinomas ([Table I](#tI-or-0-0-7177){ref-type="table"}), were evaluated in the present study. Each of the patients provided a bile sample and paired formalin-fixed paraffin-embedded (FFPE) tumor tissue samples were obtained from the clinical sample bank at the Department of Biliary II, Shanghai Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University. The samples were collected from August 2017 to March 2018. Patient status was confirmed by surgical pathology, and FFPE specimens were reviewed by a pathologist to ensure a cancer cell content ≥20%. All of the patients provided written informed consent for the examination of their samples and the use of their clinical data.

### DNA extraction from FFPE and bile samples

To extract DNA from FFPE samples, 4-µm thick sections were processed using a QIAamp DNA FFPE Tissue Kit (Qiagen) according to the manufacturer\'s instructions. The DNA concentrations were determined using a Qubit™ 3.0 Fluorometer (Thermo Fisher Scientific, Inc.), and size distributions were analyzed using LabChip GX Touch 24 nucleic acid analyzer (PerkinElmer, Inc.). To obtain bile cfDNA, bile (3 ml) was collected in 4 ml BD Vacutainer blood collection tubes (BD Biosciences) and processed within 1 h after collection. First, the bile samples were centrifuged at 1,600 × g for 15 min at room temperature, and the supernatants were carefully transferred to new 2-ml tubes (Eppendorf). The samples were then centrifuged at 16,000 × g for 10 min at room temperature, and the supernatants were collected and examined under a light microscope to ensure that there were no residual cells or debris. Samples were then aliquoted and stored at −80°C. Bile cfDNA was extracted using a QIAamp Circulating Nucleic Acid kit (Qiagen) according to the manufacturer\'s instructions. Bile cfDNA concentrations were determined using a Qubit dsDNA HS Assay kit (Life Technologies; Thermo Fisher Scientific, Inc.), and cfDNA size distributions were analyzed by Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.).

### Tumor tissue analysis by targeted deep sequencing and variant calling

Tumor tissues from the 10 BTC patients were analyzed utilizing a previously established targeted deep sequencing method ([@b15-or-0-0-7177]). Experimental procedures and variant calling were performed as previously described, with 150 tumor-associated genes examined ([Table SI](#SD1-or-0-0-7177){ref-type="supplementary-material"}). This 150-gene list of targeted deep sequencing was comprised of highly recurrent and known important regulatory genes of biliary tract carcinoma, such as *TP53, KRAS, NRAS, ERBB2, ERBB3, CDKN2A, PIK3CA, NF1*, among others. The cut-off of mutant allele frequencies (MAFs) in tumor tissue was ≥0.01.

### Bile cell-free DNA analysis by targeted deep sequencing and variant calling

Bile cfDNA samples were evaluated using a previously established targeted deep sequencing platform for cfDNA with a unique identification (UID) indexed capturing-based sequencing (UC-Seq) to establish a mutational profile ([@b11-or-0-0-7177]). The same gene panel that was used for the tumor samples was also utilized. Prior to sequencing, the bile cfDNAs were fragmented into sizes ranging from 200 to 400 bp using the Covaris S2 Sonolab (Covaris, Inc.), with the remaining procedures and variant calling performed as previously described ([@b11-or-0-0-7177]). The cut-off of mutant allele frequencies (MAFs) in bile cfDNA was ≥0.001.

### Statistical analysis

A Fisher\'s exact test was used to assess the significance and sensitivity differences for identifying mutations within groups, such as the sample collection, cancer stage, and tumor site. A P-value ≤0.05 was considered to indicate a statistically significant difference.

Results
=======

### Clinical information of BTC patients

In the present study, 10 BTC patients (four males and six females) with a median age of 68 years (range: 44--74) at the time of diagnosis ([Table I](#tI-or-0-0-7177){ref-type="table"}) were examined. Four of the patients had gallbladder carcinomas and six had bile duct cancer (one intrahepatic, four hilar, and one distal cholangiocarcinoma). Based on the seventh edition of the American Joint Committee on Cancer (AJCC) staging system for BTC ([@b16-or-0-0-7177]), four (40%) patients had stage II, three (30%) patients had stage III, and three (30%) patients had stage IV ([Table I](#tI-or-0-0-7177){ref-type="table"}). Four patients carried gallbladder stones and cholecystitis, while the other six patients did not. Percutaneous transhepatic cholangial drainage (PTCD) and operation are regarded as two different methods of extracting the bile. The origin of the obtained bile was respectively the gallbladder (four patients), the intrahepatic bile duct (one patient), the hilar bile duct (four patients) and the distal bile duct (one patient). Out of the 10 patients with BTCs, eight received a radical resection (R0), while the other two patients underwent R1 and R2 resections.

### Bile cfDNA fragment size distributions

To examine the distributions of bile cfDNA fragments, samples were analyzed using an Agilent 2100 Bioanalyzer. The electropherograms revealed that all 10 of the samples had similar distributions, which sheared to \~6,000 bp ([Fig. 1](#f1-or-0-0-7177){ref-type="fig"}). This result indicated that long DNA fragments are more prevalent among bile cfDNAs, which is not consistent with findings from plasma cfDNA ([@b11-or-0-0-7177]).

### BTC patient bile cfDNA mutational profiles

To explore the mutational landscape, the obtained bile cfDNA was sequenced using targeted deep sequencing, which is able to detect SNVs, Indels and CNVs concurrently, and a panel of 150 tumor-related genes was examined. The mean sequencing coverage for the bile cfDNA was over 3,000× with barcodes ([Table SII](#SD1-or-0-0-7177){ref-type="supplementary-material"}). A total of 71 unique somatic mutations, including SNVs (48%), Indels (9%), CNVs (35%), and deep deletions (8%), were revealed ([Fig. 2A](#f2-or-0-0-7177){ref-type="fig"} and [Table II](#tII-or-0-0-7177){ref-type="table"}). Further analysis of the gene mutational profiles revealed that in six of the patients, SNVs and Indels accounted for more than half of the mutations. In two of the bile cfDNA samples (Patients \#5 and \#7), only SNVs and Indels were present; while in one sample (Patient \#10), only CNVs were present ([Fig. 2B](#f2-or-0-0-7177){ref-type="fig"}). Furthermore, the mutational profiles revealed that of the SNV/Indel mutations, the highest variation was observed in *TP53* (70%), followed by *KRAS* (30%), *NOTCH1* (20%), *NOTCH2* (20%), and *KMT2A* (20%). Among the CNV mutations, low recurrent amplified genes, such as *CCNE1, ERBB2, CDKN1B, ZNF217* and *CDK6* were identified; with *CDKN2A* revealing a deep deletion ([Fig. 2C](#f2-or-0-0-7177){ref-type="fig"}). Among these genes, *NOTCH1, NOTCH2, ERBB2* and *CDK6* are of interest as potential drug targets.

### Concordance of mutations between tumor tissue and bile

To assess the performance of the targeted deep sequencing in detecting mutations in the bile cfDNA samples, the findings were compared to the paired tumor tissue DNA findings. In the tumor tissues, a total of 19 SNVs/Indels and 20 CNVs were identified as a reference ([Table III](#tIII-or-0-0-7177){ref-type="table"}). Mutational concordance percentages between paired bile cfDNA and tumor tissue DNA samples are presented in [Fig. 3](#f3-or-0-0-7177){ref-type="fig"}. With the exception of Patient \#10, the other 9 BTC patients had concordant mutations. In seven patients (70%, 7/10), \>50% mutational concordance between the bile cfDNA and tumor tissue DNA was revealed ([Fig. 3](#f3-or-0-0-7177){ref-type="fig"}). To further investigate the observed SNVs/Indel mutational concordance, the paired bile and tumor samples were further examined. Of the 19 variants detected in the tumor samples, 18 were also detected in bile cfDNA ([Fig. 4A](#f4-or-0-0-7177){ref-type="fig"}). The only discordant mutated gene was *CDH1*, whose allelic frequency was the lowest of all of the tumor tissue SNVs. Moreover, when compared with the tumor results, targeted deep sequencing of bile cfDNA revealed a high sensitivity (94.7%) and specificity (99.9%; [Fig. 4B](#f4-or-0-0-7177){ref-type="fig"}).

To further evaluate the capacity of targeted deep sequencing to detect CNVs in bile cfDNA, the paired bile and tumor samples were evaluated for concordance. Of the 20 CNVs identified in the tumor tissue, 15 were also confirmed in bile cfDNA ([Fig. 5A](#f5-or-0-0-7177){ref-type="fig"}). The genes which were identified with CNVs in bile cfDNA included *CCNE1, ERBB2, FLT1, CDK6, MET, PIK3CA* and *ROS1*, with *ERBB2, CDK6, MET, PIK3CA* and *ROS1* being of interest as potential BTC therapeutic targets. Furthermore, when compared to the tumor sample results, targeted deep sequencing of bile cfDNA had a sensitivity of 75.0% and specificity of 98.9% ([Fig. 5B](#f5-or-0-0-7177){ref-type="fig"}). These results indicated that targeted deep sequencing of bile cfDNA can confidently detect variance.

### Effects of various clinical conditions on the detection of mutations in bile cfDNA

To further evaluate the use of bile cfDNA, the methods of obtaining bile (namely percutaneous transhepatic cholangial drainage (PTCD) or operation) and the tumor stage or incidence site were examined to determine if variant detection sensitivity is impacted. In five of the patients, bile was obtained using PTCD, while in the other five it was obtained by operation ([Table I](#tI-or-0-0-7177){ref-type="table"}). When examining the detected SNV/Indels and CNVs, no significant difference in sensitivity was noted between the PTCD and operation methods (P\>0.00 and P\>0.00; [Fig. 6A](#f6-or-0-0-7177){ref-type="fig"}). Next, any potential effects on sensitivity due to tumor stage or incidence site were evaluated. The results revealed that AJCC stage II had a significantly decreased sensitivity in CNV detection when compared with other tumor stages (P\<0.05), as did having an incidence site of the distal bile duct (P\<0.05; [Fig. 6B](#f6-or-0-0-7177){ref-type="fig"}). These findings indicated that the sensitivity of tumor-matched mutation detection in bile cfDNA can be affected by tumor stage and incidence site.

Discussion
==========

Despite a real unmet need for improved BTC therapies ([@b17-or-0-0-7177]), clinical efforts to develop genotype-specific targeted therapies have largely failed due to a lack of reliable, safe, and reproducible genomic analyses. Current approaches rely on obtaining a tumor mutational profile that can then be utilized to predict sensitivity or resistance to particular therapies ([@b18-or-0-0-7177]). However, tissue sampling in BTC patients is challenging due to the anatomical complexity of the biliary tract system ([@b19-or-0-0-7177]), with many patients at an advanced stage losing the opportunity to receive personalized targeted therapy. Herein, for the first time, the integral mutational landscape of bile cfDNA was examined in 10 BTC patients. The examination of these bile cfDNA samples with targeted deep sequencing revealed a high sensitivity and specificity in detecting SNVs/Indels (94.7 and 99.9%, respectively) and CNVs (75.0 and 98.9%, respectively). Overall, this study provides a promising liquid biopsy method for evaluating clinical BTC patient samples.

Previous studies have reported that plasma cfDNA has a higher proportion of small fragments, with sizes between 150 to 200 bp, in many types of tumors or cancer cell lines ([@b11-or-0-0-7177],[@b20-or-0-0-7177]). However, DNA fragment sizes in bile cfDNAs from BTC patients had not been elucidated until now. Herein, bile cfDNA was revealed to be composed of predominantly long DNA fragments, which was not consistent with the findings in plasma cfDNA. These differences may be attributed to DNA restriction endonuclease variety or activity differences between the bile and plasma.

The landscape of BTC has been reported in several previous studies using whole exome sequencing and whole genome sequencing ([@b21-or-0-0-7177]--[@b24-or-0-0-7177]). The most recurrently mutated genes were *TP53, CDKN2A/B, KRAS, ARID1A*, and *IDH1* in intrahepatic cholangiocarcinoma (ICC); *KRAS, TP53, CDKN2A/B*, and *SMAD4* in extrahepatic cholangiocarcinoma; and *TP53, CDKN2A/B, ARID1A*, and *ERBB2* in gallbladder cancer ([@b25-or-0-0-7177]). Ras/phosphatidylinositol-4,5-bisphosphate 3-kinase signaling, p53/cell cycle signaling, and transforming growth factor-β/Smad signaling are substantially affected in ICC ([@b26-or-0-0-7177]), while ErbB signaling is the most extensively mutated pathway in gallbladder cancer samples ([@b22-or-0-0-7177]). In the present study, similar to previous research of tumor tissue, mutated *TP53, KRAS, CDKN2A, PIK3CA*, and *ERBB2* were also detected in bile cfDNA. *NOTCH1*, and *NOTCH2* mutations were recurrent in bile cfDNA from BTC patients, which was not observed in previous studies.

In a previous study examining SNVs in GBCs, bile containing cfDNA was revealed to have a high concordance rate (87.5%) with tumor tissues ([@b19-or-0-0-7177]). Considering the anatomical complexity of the biliary tract system ([@b27-or-0-0-7177]), patients not only with GBC, but also cholangiocarcinomas with different incidence sites, were evaluated in this cohort. In addition to SNVs, gene mutations such as Indels and CNVs were also profiled. This study found a high concordance between bile cfDNA and tumor tissues when examining SNVs/Indels, but a high concordance was also found when identifying CNVs, which has not been previously reported. Of the identified CNVs, *ERBB2, CDK6, MET, PIK3CA*, and *ROS1* are of interest as potential BTC therapeutic targets. These results support that targeted deep sequencing with barcodes can effectively isolate somatic mutations in bile cfDNA from BTC patients.

Percutaneous transhepatic cholangial drainage (PTCD) has been revealed to be one of the most important treatments for benign and malignant obstructive jaundice ([@b28-or-0-0-7177]--[@b30-or-0-0-7177]). Therefore, PTCD and operation were used as two different methods for obtaining bile in this study. Variant detection sensitivities were compared between the two methods and no significant difference was noted when detecting SNV/Indel or CNV mutations. These results suggest that bile cfDNA could serve as a clinically applicable liquid biopsy by means of PTCD. Retrograde endoscopy is one of the main means of minimally invasive treatment of cholangiopancreatography ([@b31-or-0-0-7177]). Inhepatobiliary pancreatic surgery, retrograde endoscopy is often recommended for cholangiocarcinoma. The effect of endoscopic bile extraction is a future study we plan to carry out.

Notably, several clinical features have been revealed to have a marked influence on variant detection sensitivity in bile cfDNA when compared with tumor tissues. In our previous study, lung cancer patients with different tumor stages exhibited a significant difference in mutational concordance between plasma cfDNA and tumor tissues ([@b11-or-0-0-7177]). Additionally, tumor stage has been revealed to affect gene mutation detection in cfDNA ([@b32-or-0-0-7177],[@b33-or-0-0-7177]). Herein, AJCC stage II was revealed to significantly decrease the sensitivity when detecting CNVs in bile cfDNA compared with other tumor stages (P\<0.05). While these findings indicate that tumor stage can potentially affect CNV detection, the sample size examined herein was small and this issue should be further examined with a larger sample size in the future. Next, any potential effects on CNV detection associated with tumor incidence site were examined. The results revealed that the distal bile duct significantly decreases the CNV detection sensitivity when compared with other incidence sites. Thus, these findings demonstrated that tumor stage and incidence site can impact variant detection sensitivity in bile cfDNA samples.

In conclusion, the present study revealed that long DNA fragments are prevalent in bile cfDNA samples and that targeted deep sequencing can reproducibly identify somatic variants in BTC bile cfDNA samples. Obtaining bile cfDNA, which is considered a minimally invasive liquid biopsy, and utilizing targeted deep sequencing has the following unique advantages: i) In BTC patients, bile is commonly drained using PTCD, thus bile samples can be obtained without additional trauma; ii) due to tumor heterogeneity, the information obtained from bile cfDNA is more comprehensive in comparison to a needle biopsy; iii) targeted deep sequencing of bile cfDNA samples is feasible, accurate, and sensitive in mutational variants, thus enabling a more personalized targeted therapeutic approach; and iv) bile cfDNA may provide a means to identify benign and malignant diseases or judge tumor recurrence in the future.
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![cfDNA fragment distributions. Representative electropherogram for a BTC bile cfDNA sample as detected by an Agilent 2100 Bioanalyzer. cfDNA, bile cell-free DNA; BTC, biliary tract cancer.](or-42-02-0549-g00){#f1-or-0-0-7177}

###### 

The mutational landscape of cfDNA from ten patients with BTC. (A) Gene mutational compositions in bile cfDNA from ten BTC patients (48% SNV, 43% CNV, and 9% Indel). (B) Gene mutational profiles illustrated independently. (C and D) Mutated genes harboring somatic variants and somatic copy number alterations. Mutation subtypes (SNV/Indel, CNV, and deep deletion) are each denoted with an individual color. Data presentation: (A) Pie charts presenting gene mutational compositions in bile cfDNA. (B) Histogram displaying the ratio of gene mutational types per person. (C and D) Heat maps presenting mutated genes and the types of bile cfDNA from the ten patients. cfDNA, bile cell-free DNA; BTC, biliary tract cancer; SNV/Indel, single nucleotide variation/insertion and deletion; CNV, copy number variation.
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![Mutational concordance between paired bile cfDNA and tumor tissue DNA samples from ten BTC patients. Green depicts the proportion of concordant mutations in a given patient, while mutations that are exclusively tumor- or bile-associated are depicted by blue or red, respectively. cfDNA, bile cell-free DNA; BTC, biliary tract cancer.](or-42-02-0549-g03){#f3-or-0-0-7177}

![Targeted deep sequencing to identify SNVs and Indels from cfDNA. (A) The concordance of SNV/Indel mutations in paired bile cfDNA and tumor tissue DNA samples from four patients with gallbladder carcinomas and six with cholangiocarcinomas. Concordance between tumor tissue DNA and bile cfDNA samples for a given SNV/Indel is depicted in green, while mutations found to be exclusively tumor- or bile-associated are depicted as blue or red, respectively. (B) The sensitivity and specificity of utilizing targeted deep sequencing to detect SNVs/Indels in bile when compared to tumor samples, with calculations performed using the four-table method. Data presentation: (A) Heat maps presenting SNV/Indel mutated genes of bile cfDNA from ten patients. (B) The SNV/Indel results of tumor tissue is regarded as the gold standard. In the SNV/Indel detection of bile cfDNA: Sensitivity=true positive/(true positive + false negative); specificity=true negative/(true negative + false positive). SNVs, single nucleotide variations; Indels, insertions and deletions; cfDNA, bile cell-free DNA.](or-42-02-0549-g04){#f4-or-0-0-7177}

![Targeted deep sequencing to detect CNVs in cfDNA. (A) The concordance of CNVs in paired bile cfDNA and tumor tissue DNA samples from ten BTC patients. Concordance between the tumor tissue DNA and bile cfDNA samples for a given CNV is depicted in green, while mutations revealed to be exclusively tumor- or bile-associated are depicted by blue or red, respectively. (B) The sensitivity and specificity of utilizing targeted deep sequencing to identify CNVs in bile cfDNA when compared to tumor samples, with calculations performed using the four-table method. Data presentation: (A) Heat maps presenting CNV mutated genes of bile cfDNA from ten patients. (B) The CNV results of tumor tissue are regarded as the gold standard. In the CNV detection of bile cfDNA: Sensitivity=true positive/(true positive + false negative); specificity=true negative/(true negative + false positive). CNVs, copy number variations; cfDNA, bile cell-free DNA.](or-42-02-0549-g05){#f5-or-0-0-7177}

![Potential effects of the bile extraction method, tumor stage and incidence site on the sensitivity of targeted deep sequencing in identifying mutations in cfDNA. (A) Bile cfDNA was obtained by PTCD or operation and the sensitivity in detecting SNVs/Indels and CNVs using targeted deep sequencing was analyzed. Sensitivities were examined based on (B) tumor stage and (C) incidence sites, with findings displayed as histograms. Statistical analysis: Fisher\'s exact test; n.s., P\>0.05 and \*\*P\<0.05 as indicated. cfDNA, bile cell-free DNA; PTCD, percutaneous transhepatic cholangial drainage; SNVs/Indels, single nucleotide variations/insertions and deletions; n.s., not significant.](or-42-02-0549-g06){#f6-or-0-0-7177}

###### 

Characteristics of ten patients with biliary tract cancer that received surgery.

  Characteristics                          N
  ---------------------------------------- ----------------------
  Age, median (range) in years             68 (44--74)
  Sex                                      
    Male                                   4
    Female                                 6
  Cancer type                              
    Gallbladder carcinoma                  4
    Cholangiocarcinomas                    6
  Incidence site                           
    Gallbladder                            4
    Intrahepatic bile duct                 1
    Hilar bile duct                        4
    Distal bile duct                       1
  AJCC stage                               
    I                                      0
    II                                     4
    III                                    3
    IV                                     3
  Operation type                           
    R0                                     8
    R1                                     1
    R2                                     1
  Gallbladder stones                       
    Yes                                    4
    No                                     6
  Cholecystitis                            
    Yes                                    4
    No                                     6
  Method of obtaining bile                 
    PTCD                                   5
    Operation                              5
  Location of obtaining bile               
    Gallbladder                            4
    Intrahepatic bile duct                 1
    Hilar bile duct                        4
    Distal bile duct                       1
  AFP, median (range) ng/ml                3.4 (2.4--8.0)
  CEA, median (range) ng/ml                4.5 (1.3--83.9)
  CA19-9, median (range) U/ml              154.6 (8.8--1,000.0)
  Total bilirubin, median (range) µmol/l   42.2 (8.8--305.6)

AFP, α-fetoprotein; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; PTCD, percutaneous transhepatic cholangial drainage.

###### 

Mutations of bile cell-free DNA from ten biliary tract cancer patients.

  Patient ID     SNV/Indel   CNV                                                                              
  -------------- ----------- ---------------- ---------------------------------------------------- ---------- ------
  Patient \#1    *TP53*      p.Q38Pfs\*5      0.498^[a](#tfn2-or-0-0-7177){ref-type="table-fn"}^   *CDK12*    Gain
                 *ERBB2*     p.D769Y          0.004                                                *ERBB2*    Gain
                 *PIK3CA*    c.1665-1G\>T     0.004                                                *CCNE1*    Gain
                                                                                                   *CDKN2A*   Loss
                                                                                                   *ZNF217*   Gain
  Patient \#2    *TP53*      p.C275F          0.037                                                *FGFR2*    Gain
                 *TP53*      p.P27Lfs\*17     0.012                                                           
                 *ARID2*     p.Q794Cfs\*45    0.014                                                           
                 *KRAS*      p.A146V          0.006                                                           
                 *TP53*      p.E180K          0.022                                                           
                 *SETD2*     p.M118I          0.015                                                           
  Patient \#3    *TP53*      p.P151T          0.022                                                *FLT1*     Gain
                 *NOTCH2*    p.T235S          0.011                                                           
  Patient \#4    *TP53*      p.V157F          0.062                                                *CCNE1*    Gain
                 *FLT4*      p.A622T          0.010                                                *CDKN2A*   Loss
                 *NOTCH1*    p.R1824Q         0.492                                                           
                 *KMT2A*     p.G3131S         0.467                                                           
                 *NOTCH2*    p.R29Q           0.028                                                           
  Patient \#5    *TP53*      c.783-2_821del   0.050                                                           
                 *CDKN2A*    p.V82E           0.169                                                           
                 *KRAS*      p.I36M           0.246                                                           
                 *IRS2*      p.Q1206R         0.592                                                           
                 *EP300*     p.P881S          0.423                                                           
                 *FAT1*      p.D850E          0.129                                                           
  Patient \#6    *TP53*      p.M237I          0.760                                                *CDK6*     Gain
                 *PDGFRA*    p.L216I          0.516                                                *MET*      Gain
                 *NF1*       p.E649\*         0.710                                                *BRAF*     Gain
                 *RNF43*     p.L706Cfs\*20    0.471                                                *PIK3CA*   Gain
                 *FGFR3*     p.K413R          0.320                                                *ALK*      Gain
                 *FGFR1*     p.G35R           0.109                                                           
                 *SPTA1*     p.N2076K         0.107                                                           
                 *PIK3R1*    p.N564D          0.034                                                           
                 *AR*        p.K778M          0.014                                                           
  Patient \#7    *KRAS*      p.G12D           0.016                                                           
                 *ATM*       p.A2626V         0.012                                                           
                 *NOTCH1*    p.R592H          0.486                                                           
                 *KMT2A*     p.P658P          0.483                                                           
                 *VEGFA*     p.T8Rfs\*78      0.385                                                           
  Patient \#8    *TP53*      p.R248W          0.533                                                *FGFR3*    Gain
                 *TSC1*      p.R190H          0.130                                                *VEGFA*    Gain
                 *ATR*       p.M211I          0.441                                                *MYC*      Gain
                 *BRCA1*     p.R762S          0.197                                                *ERBB3*    Gain
                                                                                                   *CDKN1B*   Gain
                                                                                                   *APC*      Gain
                                                                                                   *ROS1*     Gain
  Patient \#9                                                                                      *MRE11A*   Gain
                                                                                                   *MTOR*     Loss
                                                                                                   *CDKN2A*   Loss
                                                                                                   *STK11*    Loss
                                                                                                   *ERBB2*    Gain
                                                                                                   *CCNE1*    Gain
                                                                                                   *CDK6*     Gain
  Patient \#10                                                                                     *CDKN1B*   Gain
                                                                                                   *CCNE1*    Gain
                                                                                                   *ZNF217*   Gain

Mutation allele frequency in bile cell-free DNA sample. SNV/Indel, single nucleotide variation/insertion and deletion; CNV, copy number variation.

###### 

Mutations of tumor tissue from ten biliary tract cancer patients.

  Patient ID     SNV/Indel   CNV                                                                             
  -------------- ----------- ---------------- --------------------------------------------------- ---------- ------
  Patient \#1    *TP53*      p.Q38Pfs\*5      0.30^[a](#tfn3-or-0-0-7177){ref-type="table-fn"}^   *CDK12*    Gain
                 *CDH1*      p.Q610\*         0.07                                                *ERBB2*    Gain
                                                                                                  *CCNE1*    Gain
                                                                                                  *CDKN2A*   Loss
  Patient \#2    *TP53*      p.C275F          0.22                                                *FGFR2*    Gain
                 *TP53*      p.P27Lfs\*17     0.10                                                           
                 *ARID2*     p.Q794Cfs\*45    0.11                                                           
  Patient \#3    *TP53*      p.P151T          0.22                                                           
  Patient \#4    *TP53*      p.V157F          0.49                                                *CCNE1*    Gain
                 *FLT4*      p.A622T          0.21                                                *CDKN2A*   Loss
  Patient \#5    *TP53*      c.783-2_821del   0.07                                                           
                 *CDKN2A*    p.V82E           0.19                                                           
                 *KRAS*      p.I36M           0.35                                                           
  Patient \#6    *TP53*      p.M237I          0.08                                                *MSH6*     Loss
                 *PDGFRA*    p.L216I          0.12                                                           
                 *NF1*       p.E649\*         0.08                                                           
                 *RNF43*     p.L706Cfs\*20    0.07                                                           
  Patient \#7    *KRAS*      p.G12D           0.19                                                           
                 *ATM*       p.A2626V         0.16                                                           
  Patient \#8    *TP53*      p.R248W          0.24                                                *FGFR3*    Gain
                 *TSC1*      p.R190H          0.23                                                *VEGFA*    Gain
                                                                                                  *MYC*      Gain
                                                                                                  *ERBB3*    Loss
  Patient \#9                                                                                     *MRE11A*   Gain
                                                                                                  *MTOR*     Loss
                                                                                                  *CDKN2A*   Loss
                                                                                                  *STK11*    Loss
  Patient \#10                                                                                    *MTOR*     Gain
                                                                                                  *SPEN*     Gain
                                                                                                  *NOTCH1*   Gain
                                                                                                  GNA11      Gain

Mutation allele frequency in DNA sample from tumor tissue. SNV/Indel, single nucleotide variation/insertion and deletion; CNV, copy number variation.

[^1]: Contributed equally
